微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 8.94% | -68.59% | -53.26% | 144/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 19.13% | -14.25% | -27.48% | 140/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 26.38% | 2.16% | 2.22% | 126/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 25.81% | -4.84% | -9.34% | 129/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 28.47% | 7.11% | 27.59% | 122/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 22.31% | 7.31% | -13.61% | 138/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 25.83% | 3.1% | -4.78% | 130/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 27.12% | 8.26% | 2.05% | 127/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 26.58% | -11.27% | 27.83% | 125/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 20.79% | -5.85% | -17% | 142/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 25.05% | 6.05% | -0.02% | 127/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 25.05% | 10.67% | -16.36% | 134/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 29.95% | 23.56% | 35.64% | 114/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 22.08% | 87.41% | -6.51% | 144/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 23.62% | 85.63% | 4.33% | 125/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 22.64% | 97.59% | -6.61% | 136/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 24.24% | 42.26% | 105.74% | 114/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 11.78% | -51.72% | -7.4% | 142/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 12.72% | -50.7% | 11.05% | 116/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 11.46% | -51.9% | -32.76% | 127/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 17.04% | -24.83% | -30.18% | 107/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 24.41% | -4% | -5.44% | 126/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 25.81% | 2.35% | 8.35% | 101/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 23.82% | -16.05% | 5.08% | 108/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 22.67% | -27.37% | -10.83% | 100/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 25.42% | 9.36% | 0.81% | 123/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 25.22% | 31.93% | -11.13% | 97/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 28.38% | 37.72% | -9.09% | 95/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 31.21% | 55.45% | 34.27% | 86/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 23.25% | -30.85% | 21.62% | 115/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 19.12% | 2% | -7.23% | 95/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 20.6% | -46.7% | 2.61% | 100/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 20.08% | 2% | -40.27% | 84/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 33.62% | -24.02% | -13.04% | 82/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 38.66% | 2% | -12.63% | 54/159 | 46.2% | 贝达药业 | 95.89% | 行业排名> |
| 2015-12-31 | 44.25% | -4.77% | -4.77% | 50/159 | 46.24% | 微芯生物 | 97.46% | 行业排名> |